Business Wire

ESI-GROUP

18.1.2023 14:36:39 CET | Business Wire | Press release

Share
ESI Group Reinforces Its Commitment to Gender Equality at Work and Signs the United Nations Women's Empowerment Principles

Regulatory News:

ESI Group (ISIN Code: FR0004110310, Symbol: ESI), a global simulation and virtual prototyping software partner for the industry, has signed the United Nations Women's Empowerment Principles (WEP). The Group reaffirms its commitment to an inclusive corporate culture, guaranteeing equality between women and men: diversity at the service of the company's performance.

"By becoming a signatory to the Women's Empowerment Principles, ESI Group is committed to taking bold steps to advance gender equality in the workplace, marketplace and within the community. The Group will focus on non-discrimination, public reporting of progress toward gender equality, and on providing equal opportunities for education, training, and professional development. Diversity is key to accelerating a company's performance, enriching its culture, and employee well-being. At ESI, the workforce is multicultural, international, and comes from different areas of expertise. Women make up 43% of the Board of Directors and 50% of the management team, yet women are still underrepresented everywhere else. I am convinced that we can do better in this area and that rapidly improving the ratio of women to men in all teams will help our company to progress, satisfy employees and clients, and establish long-term performance," declares Cristel de Rouvray, CEO at ESI Group.

A priority objective for the Group

ESI Group is already committed to gender equality, notably through actions taken to promote the recruitment of women and their professional development within the industry. In May 2022, the Group set up its Women@ESI network, which strives towards strengthening internal collaboration between employees and creating a communication channel to share ideas that promote the representation of women. ESI Group confirms its intention to continue to move further.

Among the various actions in progress and to come, ESI Group will continue its policy of compensation promoting equality between women and men, based on objective market data that takes into account the position held and the level of seniority without gender consideration. ESI plans to reach 25% of women in the company by 2024 and 33% by 2028. The Group will strengthen the inclusiveness of its job offers and recruitment processes, by systematically presenting a selection of candidates composed of women and men. Furthermore, in order to materialize a safe and inclusive Group culture, ESI is committed to developing, in addition to its ethical charter, a charter further strengthening its commitment to preventing harassment. The Group will also provide a specific training on the subject of harassment to all staff. Finally, ESI Group wishes to implement a global parental leave policy for women and men by 2028.

Established by UN Global Compact and UN Women in 2010, the Women's Empowerment Principles, are informed by international labor and human rights standards and grounded in the recognition that businesses have a stake in, and a responsibility for, gender equality and women’s empowerment. There are a set of seven principles offering guidance to business on how to promote gender equality and women’s empowerment in the workplace, marketplace and community:

- 1: Establish high-level corporate leadership for gender equality,
- 2: Treat all women and men fairly at work – respect and support human rights and non-discrimination,
- 3: Ensure the health, safety and well-being of all women and men workers,
- 4: Promote education, training and professional development for women,
- 5: Implement enterprise development, supply chain and marketing practices that empower women,
- 6: Promote equality through community initiatives and advocacy,
- 7: Measure and publicly report on progress to achieve gender equality.

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1100 people around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye